Multiple Sclerosis | Unmet Need | Relapsing Remitting Multiple Sclerosis | US/EU | 2016

An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS. Nevertheless, all approved drugs present clinical shortcomings, and opportunity lingers for a DMT that can present an even more-favorable balance of potent and low risk. Meanwhile, the development of neuroprotective and remyelinating strategies remains a critical goal. This Unmet Need content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the treatment of RR-MS, and the current level of unmet need in this area. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.

Login to access report

launch Related Market Assessment Reports